Margulis V - Search Results

1

Loss of type III transforming growth factor-beta receptor expression is due to methylation silencing of the transcription factor GATA3 in renal cell carcinoma.

Cooper SJ, Zou H, Legrand SN, Marlow LA, von Roemeling CA, Radisky DC, Wu KJ, Hempel N, Margulis V, Tun HW, Blobe GC, Wood CG, Copland JA. Cooper SJ, et al. Among authors: margulis v. Oncogene. 2010 May 20;29(20):2905-15. doi: 10.1038/onc.2010.64. Epub 2010 Mar 8. Oncogene. 2010. PMID: 20208565 Free PMC article.

2

Renal cell carcinoma clinically involving adjacent organs: experience with aggressive surgical management.

Margulis V, Sánchez-Ortiz RF, Tamboli P, Cohen DD, Swanson DA, Wood CG. Margulis V, et al. Cancer. 2007 May 15;109(10):2025-30. doi: 10.1002/cncr.22629. Cancer. 2007. PMID: 17420980 Free article.

3

Redefining pT3 renal cell carcinoma in the modern era: a proposal for a revision of the current TNM primary tumor classification system.

Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Margulis V, et al. Cancer. 2007 Jun 15;109(12):2439-44. doi: 10.1002/cncr.22713. Cancer. 2007. PMID: 17487856 Free article.

4

Update on staging controversies for locally advanced renal cell carcinoma.

Margulis V, Wood CG. Margulis V, et al. Expert Rev Anticancer Ther. 2007 Jul;7(7):909-14. doi: 10.1586/14737140.7.7.909. Expert Rev Anticancer Ther. 2007. PMID: 17627450 No abstract available.

5

Location of extrarenal tumor extension does not impact survival of patients with pT3a renal cell carcinoma.

Margulis V, Tamboli P, Matin SF, Meisner M, Swanson DA, Wood CG. Margulis V, et al. J Urol. 2007 Nov;178(5):1878-82. doi: 10.1016/j.juro.2007.07.011. Epub 2007 Sep 17. J Urol. 2007. PMID: 17868733

6

Oncological efficacy and safety of nephron-sparing surgery for selected patients with locally advanced renal cell carcinoma.

Margulis V, Tamboli P, Jacobsohn KM, Swanson DA, Wood CG. Margulis V, et al. BJU Int. 2007 Dec;100(6):1235-9. doi: 10.1111/j.1464-410X.2007.07225.x. BJU Int. 2007. PMID: 17979923

7

Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?

Margulis V, Wood CG. Margulis V, et al. Eur Urol. 2008 Sep;54(3):489-92. doi: 10.1016/j.eururo.2007.12.041. Epub 2008 Jan 11. Eur Urol. 2008. PMID: 18206292 No abstract available.

8

Analysis of clinicopathologic predictors of oncologic outcome provides insight into the natural history of surgically managed papillary renal cell carcinoma.

Margulis V, Tamboli P, Matin SF, Swanson DA, Wood CG. Margulis V, et al. Cancer. 2008 Apr 1;112(7):1480-8. doi: 10.1002/cncr.23322. Cancer. 2008. PMID: 18240184 Free article.

9

Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Margulis V, et al. J Urol. 2008 Jul;180(1):94-8. doi: 10.1016/j.juro.2008.03.047. Epub 2008 May 15. J Urol. 2008. PMID: 18485389

10

Is patient performance status always an accurate surrogate for predicting tumor biology in patients with metastatic renal cancer?

Margulis V, Wood CG. Margulis V, et al. Cancer. 2008 Sep 15;113(6):1282-3. doi: 10.1002/cncr.23709. Cancer. 2008. PMID: 18661508 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

425 results

Search Page

Filters